Single HDM/ASCT Non-inferior to Tandem HDM/ASCT in Newly Diagnosed Multiple Myeloma

Share this content:
Single high-dose melphalan/autologous transplantation was non-inferior to tandem HDM/ASCT in patients with multiple myeloma.
Single high-dose melphalan/autologous transplantation was non-inferior to tandem HDM/ASCT in patients with multiple myeloma.

Single high-dose melphalan/autologous transplantation (HDM/ASCT) was non-inferior to tandem HDM/ASCT in patients with multiple myeloma, according to a study published in the British Journal of Haematology.1

Investigators sought to determine whether single (arm A) versus tandem (arm B ) HDM/ASCT was non-inferior in terms of 2-year event-free survival (EFS) in patients with newly diagnosed multiple myeloma in this prospective, randomized phase 3 trial.

A total of 358 evaluable patients were included in the intention-to-treat population; 177 patients were in arm A and 181 were in arm B.

Results showed that after a median follow-up of more than 11 years, non-inferiority was demonstrated using the planned non-inferior threshold of 15% of the 2-year EFS rate. No differences were found in the EFS or overall survival rates (P = .53; P = .33, respectively).

This was consistent with the results of a per-protocol analysis, which included patients who received the intervention (single/tandem HDM/ASCT; 156 patients/93 patients) and those who did not receive a second HDM/ASCT due to medical reasons (12%). A total of 26% of patients in the tandem arm refused a second HDM/ASCT due to non-medical reasons.

RELATED: Single-agent Cabozantinib Lacks Activity in R/R Myeloma

The rates of complete responses increased from first to second HDM/ASCT  in both the intention-to-treat and per-protocol set of the tandem arm (both P = .04). Ten-year overall survival for the entire intention-to-treat population was 34% (95% CI, 29 – 40). Overall survival after first relapse was significantly shortened in the tandem arm (P = .04).

Reference

  1. Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial [published online ahead of print March 17, 2016]. Br J Haematol. doi: 10.1111/bjh.13994.

Single high-dose melphalan/autologous transplantation (HDM/ASCT) was non-inferior to tandem HDM/ASCT in patients with multiple myeloma, according to a study published in the British Journal of Haematology.1

 

Investigators sought to determine whether single (arm A) versus tandem (arm B ) HDM/ASCT was non-inferior in terms of 2-year event-free survival (EFS) in patients with newly diagnosed multiple myeloma in this prospective, randomized phase 3 trial.

 

A total of 358 evaluable patients were included in the intention-to-treat population; 177 patients were in arm A and 181 were in arm B.

 

Results showed that after a median follow-up of more than 11 years, non-inferiority was demonstrated using the planned non-inferior threshold of 15% of the 2-year EFS rate. No differences were found in the EFS or overall survival rates (P = .53; P = .33, respectively).

 

This was consistent with the results of a per-protocol analysis, which included patients who received the intervention (single/tandem HDM/ASCT; 156 patients/93 patients) and those who did not receive a second HDM/ASCT due to medical reasons (12%). A total of 26% of patients in the tandem arm refused a second HDM/ASCT due to non-medical reasons.

 

The rates of complete responses increased from first to second HDM/ASCT  in both the intention-to-treat and per-protocol set of the tandem arm (both P = .04). Ten-year overall survival for the entire intention-to-treat population was 34% (95% CI, 29 – 40). Overall survival after first relapse was significantly shortened in the tandem arm (P = .04).

 

Reference

1. Mai EK, Benner A, Bertsch U, et al.

 

Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial [published online ahead of print March 17, 2016]. Br J Haematol. doi: 10.1111/bjh.13994

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters